Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Free Cash Flow (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Free Cash Flow for 9 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 8.31% year-over-year to $14.3 million, compared with a TTM value of $41.7 million through Dec 2025, up 7.22%, and an annual FY2025 reading of $41.7 million, up 7.22% over the prior year.
  • Free Cash Flow was $14.3 million for Q4 2025 at Puma Biotechnology, up from $9.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $17.3 million in Q3 2022 and bottomed at -$26.9 million in Q1 2022.
  • Average Free Cash Flow over 5 years is $5.6 million, with a median of $10.1 million recorded in 2023.
  • The sharpest move saw Free Cash Flow crashed 18648.65% in 2022, then skyrocketed 1290.86% in 2025.
  • Year by year, Free Cash Flow stood at -$5.4 million in 2021, then surged by 241.36% to $7.7 million in 2022, then skyrocketed by 35.74% to $10.4 million in 2023, then skyrocketed by 50.03% to $15.6 million in 2024, then decreased by 8.31% to $14.3 million in 2025.
  • Business Quant data shows Free Cash Flow for PBYI at $14.3 million in Q4 2025, $9.7 million in Q3 2025, and $14.1 million in Q2 2025.